This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Iovance Biotherapeutics’s 8K filing here.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Featured Articles
- Five stocks we like better than Iovance Biotherapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 11/4 – 11/8
- When to Sell a Stock for Profit or Loss
- Trump’s Return: Which Sectors Will Benefit Most?
